Cited by 132Gastrointestinal Bleeding Diagnosis and TreatmentHelicobacter pylori-related gastroenterology studiesGastroesophageal reflux and treatments

Meta‐analysis: proton‐pump inhibition in high‐risk patients with acute peptic ulcer bleeding

Open access
Bardou, M., Toubouti, Y., Benhaberou‐Brun, D., Rahme, E., Barkun, A. N.·2005·Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background: Recent data suggest that profound acid suppression may improve outcomes of patients in peptic ulcer bleeding. Aim: To better characterize the role of different pharmacological therapies in this population. Methods: MEDLINE was used to identify randomized trials (01/1990–04/2003) that assessed the efficacy of pharmacological treatments for patients with bleeding peptic ulcers exhibiting high‐risk stigmata (Forrest Ia–IIb). Three groups of treatment were assessed: proton‐pump inhibitors given as high‐dose bolus followed by intravenous constant infusion (40–80 mg and at least 6 mg/h), high‐dose oral proton‐pump inhibitors (at least twice the standard dosage), non‐high‐dose proton‐pump inhibitors (other proton‐pump inhibitors dosing schedules). Mixed‐effect models were used to determine rate differences between treatment and control groups. Results: Eighteen studies (1855 patients) were included. High‐dose intravenous proton‐pump inhibitors significantly reduced rebleeding (−14.6%), surgery (−5.4%) and mortality (−2.7%) compared with placebo, and rebleeding (−20.6%) compared with H 2 RA. Compared with placebo, high‐dose oral proton‐pump inhibitors significantly reduced only rebleeding (−11.8%), while non‐high‐dose proton‐pump inhibitor treatment significantly improved all three outcomes. Conclusions: High‐dose intravenous proton‐pump inhibitor significantly decreases ulcer rebleeding, surgery and mortality. Early data on high‐dose oral proton‐pump inhibitor suggest improved rebleeding. The non‐high‐dose proton‐pump inhibitor regimens, including a broad range of dosing, also improved outcomes, suggesting that doses inferior to those in the high‐dose intravenous proton‐pump inhibitor may be effective.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2005.02391.x

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PPIs are the first-choice treatment for acid-related disorders such as bleeding, peptic ulcers, gastroesophageal reflux, erosive esophagitis (ERD) and certain dyspepsia subtypes.

    “PPIs are the first-choice treatment for acid-related disorders such as bleeding, peptic ulcers, gastroesophageal reflux, erosive esophagitis (ERD) and certain dyspepsia subtypes[2-5].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 2

  1. Zed PJ, Loewen PS, Slavik RS, Marra CA. Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers. Ann Pharmacother 2001; 35: 1528-34.
  2. Barkun A, Martel M, Toubouti Y, Strazzulla J, Petit M. Is there a threshold PPI dose that decreases non lethal outcomes in patients with non variceal upper GI bleeding? Gastroenterology 2004; 126: W1275.

Cited by

Sorted by citations

Authors
Bardou, M., Toubouti, Y., Benhaberou‐Brun, D., Rahme, E., & Barkun, A. N.
Affiliations
Montreal General Hospital (CA)
Corresponding author
Bardou, M.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2005-03
Volume
21
Issue
6
Pages
677-686
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2140819427
Cited by
132
References
64
Citations by year
2025: 3 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 3 · 2015: 4 · 2014: 3 · 2013: 3 · 2012: 8
FWCI
2.55
Type
journal article
Language
en
Open access
Locations
  • Alimentary Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • AstraZeneca
  • AstraZeneca Canada
  • McGill University
  • Arthritis Society
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal Bleeding Diagnosis and Treatment
  • Health Sciences › Medicine › Surgery › Helicobacter pylori-related gastroenterology studies
  • Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
Keywords
proton pump inhibitors, peptic ulcer bleeding, ulcer rebleeding, Forrest classification, acid suppression, H2 receptor antagonists, mortality
MeSH terms
Administration, Oral, Dose-Response Relationship, Drug, Humans, Infusions, Intravenous, Peptic Ulcer Hemorrhage, Randomized Controlled Trials as Topic, Treatment Outcome, Proton Pump Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review